Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Medical Univ. HIF-1α compound 3s
- Development stage
- Unknown
- Lead developer
- China Medical University
01
Overview
China Medical Univ. HIF-1α compound 3s: sourced facts only. name: "Compound 3s was identified as the most promising HIF-1α inhibitor due to its exceptional antiproliferative effects, with IC50 values of 0.6 and 53.3 nM observed in MiaPaCa-2 and MDA-MB-231 cells, respectively." [PMID:37728024]; target: "Compound 3s was identified as the most promising HIF-1α inhibitor due to its exceptional antiproliferative effects, with IC50 values of 0.6 and 53.3 nM observed in MiaPaCa-2 and MDA-MB-231 cells, respectively." [PMID:37728024]; developer: "School of Pharmacy, College of Pharmacy, China Medical University, Taichung, 40604, Taiwan." [PMID:37728024]
02
Targets
HIF1A (Hypoxia-inducible factor 1-alpha)
Beyond the preview
Go deeper on China Medical Univ. HIF-1α compound 3s.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Medical Univ. HIF-1α compound 3s.